» Articles » PMID: 37629478

Addressing Symptom Burden and Palliative Care Needs in Cystic Fibrosis: A Narrative Review of the Literature

Overview
Journal Life (Basel)
Specialty Biology
Date 2023 Aug 26
PMID 37629478
Authors
Affiliations
Soon will be listed here.
Abstract

Among people with cystic fibrosis (CF), illness burden is multifaceted, and symptoms may fluctuate in intensity across a lifespan. Caregivers of people with CF may also experience distressing symptoms. Recent developments in CF care, including the availability of highly effective modulator therapies (HEMTs) and new palliative care guidelines promoting palliative care screening may help alleviate symptoms. The objective of this review was to present a narrative view of the recent literature on symptom burden in CF, new screening approaches informed by the Cystic Fibrosis Foundation (CFF) palliative care guidelines, and early data from studies examining the impact of HEMTs on CF symptom burden. A review of the relevant literature was conducted using Google Scholar and PubMed. Included articles covered approaches to burden assessment in CF and other chronic illnesses, epidemiology of CF symptom burden, the impact of HEMTs on symptom burden, and the CFF palliative care guidelines. A primary palliative care model implementing the CFF guidelines was also described. Results of this review show that while recent developments in CF care have led to a reduction in physical symptoms, mental health symptoms remain prevalent. Ongoing screening and triage can ensure that physical symptoms, psychological symptoms, social needs, practical problems, and communication concerns are addressed by care teams.

Citing Articles

The impact of elexacaftor/tezacaftor/ivacaftor on cystic fibrosis health-related quality of life and decision-making about daily treatment regimens: a mixed methods exploratory study.

Basile M, Polo J, Henthorne K, DeCelie-Germana J, Galvin S, Wang J Ther Adv Chronic Dis. 2024; 15:20406223241264477.

PMID: 39091508 PMC: 11292704. DOI: 10.1177/20406223241264477.

References
1.
Spitzer R, Kroenke K, Williams J, Lowe B . A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006; 166(10):1092-7. DOI: 10.1001/archinte.166.10.1092. View

2.
Schechter M, Ostrenga J, Fink A, Barker D, Sawicki G, Quittner A . Decreased survival in cystic fibrosis patients with a positive screen for depression. J Cyst Fibros. 2020; 20(1):120-126. DOI: 10.1016/j.jcf.2020.07.020. View

3.
Eckerblad J, Theander K, Ekdahl A, Jaarsma T . Symptom trajectory and symptom burden in older people with multimorbidity, secondary outcome from the RCT AGe-FIT study. J Adv Nurs. 2016; 72(11):2773-2783. DOI: 10.1111/jan.13032. View

4.
Collins S, Jones A, Woodward S, Sturt J . The experience of living with and managing cystic fibrosis related diabetes: a qualitative review. J Res Nurs. 2022; 27(8):735-753. PMC: 9755567. DOI: 10.1177/17449871221116970. View

5.
Dellon E, Goggin J, Chen E, Sabadosa K, Hempstead S, Faro A . Defining palliative care in cystic fibrosis: A Delphi study. J Cyst Fibros. 2017; 17(3):416-421. DOI: 10.1016/j.jcf.2017.10.011. View